Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,616.85
(
0.08%
)
US TECH 100
24,198.00
(
2.80%
)
Dow Jones
46,584.46
(
-0.18%
)
Brent Oil
93.56
(
-7.56%
)
Bitcoin
71,706.46
(
-0.39%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

MobyInvestor

Send PM Follow Ignore
Followers 4
Posts 1467
Boards Moderated 0
Alias Born 11/20/2007

MobyInvestor

Re: Thurly post# 54696

Monday, 08/02/2010 10:23:08 AM

Monday, August 02, 2010 10:23:08 AM

Post# of 347009
Define "require" please.

I'm going to assume that you fully comprehend what "require" means.

Now, if "common short-term side effects and risks associated with the drug" are safety issues and they are required to be evaluated during phase II, please explain the lack of any flagged safety issues for the primary or secondary outcome measures in 3 of the 5 phase II Bavi AC trials.

Regards,

moby
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote